Edwards Lifesciences Corp
EW: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$43.00 | Qjjghy | Pywxhydbd |
Edwards Earnings: Broad-Based Growth Supported by Procedure Volume and New Product Cycles
Edwards Lifesciences posted solid second-quarter results, with top-line growth putting it on track to slightly exceed our full-year expectations and the bottom line closely tracking with our projections. Our small adjustments were immaterial to our $86 fair value estimate. Edwards’ established reputation for innovation was on display again this quarter, solidifying the intangible assets that support its narrow economic moat.